Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

GEN Announces First Patient Dosed in Phase II Clinical Trial of SUL-238 in Parkinson's Disease

Summary by The Batesville Daily Guard
Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's disease.

1 Articles

The Batesville Daily GuardThe Batesville Daily Guard
Lean Right

GEN Announces First Patient Dosed in Phase II Clinical Trial of SUL-238 in Parkinson's Disease

Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's disease.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Batesville Daily Guard broke the news on Monday, June 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Parkinson's Disease icon

Parkinson's Disease

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal